Jazz Pharmaceuticals’ Xywav Approved for Narcolepsy By Sam | July 22, 2020 The FDA required a boxed warning for the drug because of its potential for misuse and abuse. Source: Devices & Diagnostics Letter Posted in Devices & Diagnostics Letter